Results of Acute Lymphoblastic Leukemia Therapy in Childhood with a Modified BFM Protocol in a Multicenter Study in the German Democratic Republic

  • F. Zintl
  • W. Plenert
  • H. Malke
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 30)


Considerable progress in the treatment of acute lymphoblastic leukemia (ALL) has been made in the last 30 years, particularly childhood ALL. The basis of this progress has been modern multidisciplinary management and controlled clinical trials. The most important problem in the therapy of ALL in childhood is the relapse of leukemia. From 1978 to 1981, we did not succeed in raising the relapse-free survival of children with high-risk factors above 30% [1] with the LSA2L2 protocol [2]. In a study carried out from 1970 to 1976 [3], it was shown that the intensification and prolongation of the remission-induction phase resulted in a higher percentage of relapse-free long-term survival. We adopted the principles of the BFM protocol in 1981 and started the controlled and randomized multicentric ALL study VII/81.


Acute Lymphoblastic Leukemia German Democratic Republic Bone Marrow Relapse Reinduction Therapy High Risk Acute Lymphoblastic Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zintl F, Hermann J, Katenkamp D, Malke H, Plenert W (1983) Results of LSA2L2 therapy in children with high risk acute lymphoblastic leukemia and non-Hodgkin’s lymphoma. In: Neth R, Gallo RG, Greaves MF, Moore MAS, Winkler K (eds) Modern trends in human leukemia V. Springer, Berlin Heidelberg New York, pp 62–66CrossRefGoogle Scholar
  2. 2.
    Wollner N, Burchenal JH, Lieberman PH, Exelby P, D’Angio G, Murphy ML (1976) Non-Hodgkin’s lymphoma in children. Cancer 37: 123–134PubMedCrossRefGoogle Scholar
  3. 3.
    Riehm H, Gadner H, Henze G, et al. (1980) The Berlin childhood acute lymphoblastic leukemia therapy study 1970–1976. Am J Pediatr Hematol Oncol 2: 299–306Google Scholar
  4. 4.
    Langermann HJ, Henze G, Wulf M, Riehm H (1982) Abschätzung der Tumorzellmassen bei der akuten lymphoblastischen Leukämie im Kindesalter: Prognostische Bedeutung und praktische Anwendung. Klin Padiat 194: 209–213Google Scholar
  5. 5.
    Kaplan EL, Meier P (1980) Nonparametric estimation from incomplete observation. J Am Statist Assoc 53: 457–481CrossRefGoogle Scholar
  6. 6.
    Miller DR, Leikin S, Albo V, et al. (1981) Prognostic importance of morphology (FAB classification) in childhood acute lymphoblastic leukemia ( ALL ). Br J Haematol 48: 199–206Google Scholar
  7. 7.
    Miller DR, Leikin S, Albo V, et al. (1983) Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141. Cancer 51: 1041–1049PubMedCrossRefGoogle Scholar
  8. 8.
    Henze G, Langermann HJ, Fengler R, et al. (1982) Therapiestudie BFM 79/81 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: Intensivierte Reinduktionstherapie für Patientengruppen mit unterschiedlichem Rezidivrisiko. 194: 195–203Google Scholar
  9. 9.
    Zintl F, Malke H, Plenert W (1985) Clinical experiences with a modified BFM protocol in childhood acute lymphoblastic leukemia. In: Neth R, Gallo RC, Greaves MF, Janke G (eds) Modern trends in human leukemia VI, Springer, Berlin Heidelberg New York, pp 84–89Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • F. Zintl
    • 1
  • W. Plenert
    • 1
  • H. Malke
    • 1
  1. 1.Department of Pediatrics and GDR Working Group for Pediatric Hematology and OncologyUniversity of JenaJenaGerman Democratic Republic

Personalised recommendations